Preclinical validation of a novel compound targeting p70S6 Kinase in breast cancer

SOL784Poster
Written By James Cotton
James Cotton
Previous

CASC-578, a novel Chk1 inhibitor, is active as a single agent in solid tumors and displays synergistic anti-tumor activity in combination with Wee1 inhibition
Next

Preclinical validation of a novel compound targeting p70S6 kinase in breast cancer